Evidence map›Paper›PMID 37886518›Full record

ArticleResearch square2023

Human CD4-Binding Site Antibody Elicited by Polyvalent DNA Prime-Protein Boost Vaccine Neutralizes Cross-Clade Tier-2-HIV Strains.

Shixia Wang, Kun-Wei Chan, Danlan Wei, Xiuwen Ma, Shuying Liu, Guangnan Hu, Saeyoung Park, Ruimin Pan, Ying Gu, Alexandra F Nazzari and 12 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 10 institutions in 4 countries.

Shixia WangDepartment of Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.ORCID 0000-0002-7748-8468
Kun-Wei ChanDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY 10016, USA.ORCID 0000-0001-5384-6198
Danlan WeiLaboratory of Immune Regulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Xiuwen MaDepartment of Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Shuying LiuSYL Consulting, Thousand Oak, CA 91320, USA.
Guangnan HuDepartment of Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Saeyoung ParkDepartment of Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Ruimin PanDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Ying GuVaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Alexandra F NazzariVaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Adam S OliaVaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Kai XuVaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Bob C LinVaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Mark K LouderVaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.ORCID 0000-0001-7540-9263
Nicole A Doria-RoseVaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.ORCID 0000-0002-5731-3054
David MontefioriDepartment of Surgery, Duke University, Durham, NC 27710, USA.ORCID 0000-0003-0856-6319
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
Tongqing ZhouVaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Peter D KwongVaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
James ArthosLaboratory of Immune Regulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.ORCID 0000-0002-6767-4267
Xiang-Peng KongDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Shan LuDepartment of Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
National Institute of Allergy and Infectious Diseases · USUniversity of Massachusetts Chan Medical School · USInstitut de Recherche Vaccinale · FRNational Institutes of Health · USBeth Israel Deaconess Medical Center · USDuke University · USIndiana University School of MedicineNew York University · USNYU Langone Health · USParallel Consulting (United States) · US

Funding

Optimizing the immunogenicity of next generation polyvalent HIV vaccine formulatiU19AI082676 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LU, SHAN · 2009 to 2016
$15.8M
Vaccines to Induce Functional Antibodies Targeting the V2 Loop P01AI100151 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KONG, XIANGPENG, ZOLLA-PAZNER, SUSAN B · 2012 to 2017
$15.4M
Variation in HIV-1 R5 Envs: Consequences for tropism, neutralization & vaccinesP01AI082274 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LU, SHAN · 2009 to 2013
$9.7M
Structure and immunogenicity of novel trimeric HIV-1 Env immunogensR01AI145655 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KONG, XIANGPENG · 2019 to 2023
$4.7M
HIV Vaccine Design and Development Teams-26605394N01AI005394 · NIAID · ADVANCED BIOSCIENCES LABORATORIES, INC. · 2000 to 2005
$2.5M
Structure, function, and antigenicity of emerging henipavirus surface glycoproteinsU01AI173348 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Kai Xu · 2023 to 2026
$2.4M
Polyvalent DNA Plus Protein HIV VaccinesR01AI065250 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LU, SHAN · 2006 to 2010
$1.9M
Production of neutralizing mAbs from HIV vaccineesR33AI087191 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI WANG, SHIXIA · 2012 to 2014
$1.4M
Production of neutralizing mAbs from HIV vaccineesR21AI087191 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI WANG, SHIXIA · 2010 to 2011
$450k
Targeting glycoprotein (G) domain-III for pan-lyssavirus nanobody therapeuticsUH2AI171611 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI XU, KAI · 2023 to 2024
$423k
NIAID NIH HHS N01 AI005394NIAID NIH HHS P01 AI082274NIAID NIH HHS P01 AI100151NIAID NIH HHS R01 AI065250NIAID NIH HHS R01 AI145655NIAID NIH HHS R21 AI087191NIAID NIH HHS R33 AI087191NIAID NIH HHS U01 AI173348NIAID NIH HHS U19 AI082676NIAID NIH HHS UH2 AI171611NIGMS NIH HHS Y01 GM000080
6 · The paper itself

Abstract

The vaccine elicitation of HIV-neutralizing antibodies with tier-2-neutralization breadth has been a challenge. Here, we report the isolation and characteristics of a CD4-binding site specific monoclonal antibody, HmAb64, from a human volunteer immunized with a polyvalent gp120 DNA prime-protein boost vaccine. HmAb64 derived from heavy chain variable germline gene IGHV1-18, light chain germline gene IGKV1-39, and had a 3

Indexed as

CD4-binding siteDNA immunizationenvelope glycoproteingp120HIV-1monoclonal antibodyTier-2 neutralizationvaccine

Identifiers

PMID37886518
PMCPMC10602183
OpenAlexW4387822321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.